BioSpace News Archive

TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others.

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors.

Fact.MR – A Market Research and Competitive Intelligence Provider: Fact.MR in its latest market analysis forecasts that the atherosclerosis drugs market will register a healthy compound annual growth rate between 2021 and 2031.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported its results for the half-year ended June 30, 2021 and provided a corporate update.

Sanofi announced that its Q3 2021 Memorandum for modelling purposes is available on the “Investors” page of the company’s website.

AstraZeneca and Merck announced positive results from the Phase 3 PROpel trial, in which LYNPARZA in combination with abiraterone and prednisone demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival versus abiraterone plus prednisone as a first-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.

Celldex Therapeutics, Inc. announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 1:20 p.m. ET.

4D Molecular Therapeutics announced a late-breaking presentation of preliminary clinical data from the on-going 4D-125 Phase 1/2 trial in patients with X-Linked Retinitis Pigmentosa will be presented at the upcoming Annual Society of Retina Specialists Annual Meeting 2021 that will take place in San Antonio, TX on October 8-12, 2021.

SAB Biotherapeutics announced that an independent Data Safety Monitoring Board has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September 29, 2021